Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries GlaxoSmithKline: The Next Portfolio Vaccine? By: TalkMarkets February 14, 2019 at 15:01 PM EST The current stock price is considered overpriced for the value an investor would get in return. Dividends are satisfying, but there are no growth promises in the foreseeable future. Read More >> Related Stocks: Gsk Plc ADR Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
GlaxoSmithKline: The Next Portfolio Vaccine? By: TalkMarkets February 14, 2019 at 15:01 PM EST The current stock price is considered overpriced for the value an investor would get in return. Dividends are satisfying, but there are no growth promises in the foreseeable future. Read More >> Related Stocks: Gsk Plc ADR